Approximately 60% of patients with acral and mucosal melanoma and ~90% of patients with uveal melanoma overexpress TYRP1, and TYRP1 CAR-T cell therapy could potentially lead to clinical benefit in this patient subset. This evidence concerns the gene TYRP1 and uveal melanoma.